Observational Study of the Effectiveness and Safety of Vismodegib (Erivedge) in Patients Treated in Argentina
Observational Study of the Effectiveness and Safety of Vismodegib (Erivedge) in Patients Treated in Argentina
This observational, noninterventional study is designed to further characterize the effectiveness and safety profile of vismodegib (Erivedge) in Argentine patients. Only patients with locally advanced basal cell carcinoma (laBCC) or metastatic basal cell carcinoma (mBCC) will be considered in the effectiveness analysis. Study duration is estimated to be approximately 12 months.
Inclusion Criteria:
Exclusion Criteria: